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Objective: The n-3 polyunsaturated fatty acids are dietary components derived from ﬁsh oil with beneﬁcial cardiovascular
effects that may relate in part to anti-inﬂammatory properties. Peripheral artery disease (PAD) is characterized by
a marked proinﬂammatory state. We hypothesized that the n-3 polyunsaturated fatty acids content of red blood cells
(omega-3 index) would be correlated with biomarkers of inﬂammation and vascular function in a PAD cohort.
Methods: This was a cross-sectional study of subjects who presented to an outpatient vascular surgery clinic for evaluation
of PAD. We used linear regression to evaluate the independent association between the omega-3 index, inﬂammatory
biomarkers (C-reactive protein [CRP], intercellular adhesion molecule-1, interleukin-6, and tumor-necrosis-factor-a)
and endothelial function (brachial artery ﬂow mediated dilation).
Results: 64 subjects (61 claudicants and three with critical limb ischemia) were recruited for the study. The mean CRP
level was 5.06 5.0 mg/L, and the mean omega-3 index was 5.0%6 1.8%. In an unadjusted model, the omega-3 index was
negatively associated with CRP (38% increase in CRP for one standard deviation decrease in the omega-3 index; P [
.007), which remained signiﬁcant after adjustment for age, body mass index, smoking, ankle-brachial index, and high-
density lipoprotein (33%; P [ .04). There was also evidence for independent associations between the omega-3 index
and IL-6 (P [ .001). There were no signiﬁcant associations between the omega-3 index and vascular function tests.
Conclusions: In a cohort of patients with PAD, the omega-3 index was inversely associatedwith biomarkers of inﬂammation
even after adjustment for covariates including the ankle-brachial index. Because patients with PAD have a high inﬂam-
matory burden, further studies should be conducted to determine if manipulation of omega-3 index via dietary changes or
ﬁsh oil supplementation could improve inﬂammation and symptoms in these patients. (J Vasc Surg 2013;58:1283-90.)In a primary care setting, nearly one-third of patients
aged 70 and older will suffer from peripheral artery disease
(PAD),1 which can signiﬁcantly impact quality of life and
longevity. Despite the available medical therapies, patients
with PAD continue to have a higher risk of cardiovascular
events compared with patients with coronary artery disease
(CAD).2,3 Several studies have demonstrated that C-
reactive protein (CRP) and other inﬂammatory markers,
including interleukin (IL)-6 and intercellular-adhesion-
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development and resolution of inﬂammation,17-19 and can
improve endothelial function.20 The omega-3 indexda
measure of the red blood cell (RBC) content of the two
major long-chain n-3 PUFA, eicosapentaenoic acid and
docosahexaenoic acid, expressed as a percentage of total
RBC fatty acids (FA)dis a valid marker of tissue n-3
PUFA content and an independent, graded risk factor for
death from CAD.21 In patients with stable CAD, the
omega-3 index has been inversely associated with inﬂam-
mation as measured with CRP.22 It is important to under-
stand whether this relationship exists in patients with PAD
as well, as inﬂammation appears to be more severe in these
patients and correlates with poorer outcomes.7-10,23 The
goal of this study was to determine if the omega-3 index
is associated with circulating markers of inﬂammation and
endothelial function in patients with PAD. A better under-
standing of this relationship could help guide future treat-
ment of these patients (ie, nutritional recommendations or
supplementation) in an effort to lower inﬂammation and
improve their vascular function.
METHODS
Study population and protocol
This study was approved by the Committee on Human
Research at the University of California, San Francisco, and
all patients provided informed consent. The study included
patients referred to the outpatient vascular surgery clinic of
the San Francisco Veterans Affairs Medical Center (SF
VAMC) for evaluation of symptomatic PAD. PAD diag-
nosis was based on current guidelines of an index ankle-
brachial index (ABI) <0.9 on the affected limb(s) at
presentation with the presence of claudication or critical
limb ischemia (CLI). We excluded patients with incom-
pressible arteries or an ABI >1.4.24,25 Claudication was
diagnosed based on fatigue, discomfort, or pain that occurs
in speciﬁc limb muscle groups during effort due to
exercise-induced ischemia.26 CLI was deﬁned as limb
pain that occurs at rest or impending limb loss that is
caused by severe compromise of blood ﬂow to the affected
extremity.26 Both patients with mild-moderate (ABI of
0.41-0.90) and severe PAD (<0.40) were included in the
study.26 Additional study exclusion criteria included signif-
icant renal disease (estimated glomerular ﬁltration
rate <60 mL/min), hepatic disease, or inﬂammatory
disease, concurrent severe infections, acute illness or other
major surgery within 30 days of evaluation, or taking
immunosuppressive medications. Those meeting the study
criteria were invited to participate and informed consent
was obtained. Demographic data (including age, race,
sex, hip and waist circumference, body mass index, prior
supplement use, exercise frequency), cardiovascular history
(eg, CAD, cerebrovascular disease, previous procedures),
risk factors (hypertension, diabetes, hyperlipidemia, ciga-
rette smoking), medications, depressive symptoms (using
modiﬁed nine-item Patient Health Questionnaire-9),27
and pertinent cardiovascular examination ﬁndings wererecorded. Comorbidities reported in this study (CAD,
cerebrovascular disease, hypertension, diabetes, and hyper-
lipidemia) were based on diagnoses previously made by
treating physicians and entered in the electronic medical
record system of the SF VAMC. A total of 80 consecutive
patients meeting study criteria were screened and
approached to participate in the study (2011-2012).
Sixteen declined to participate for reasons including
distance from the hospital and time commitment.
Measurements
n-FA measurements. To measure the omega-3 index,
10 mL of whole venous blood were collected in a fasting
state in an ethylenediaminetetraacetic acid tube, and
centrifuged at 2800 rpm for 10 minutes at 4C within
30 minutes of collection. Packed RBCs were stored
at 80C until assayed for the omega-3 index according to
the high-sensitivity omega-3 index methodology.28,29
Brieﬂy, FA methyl esters are generated by acid trans-
esteriﬁcation with boron triﬂuoride and analyzed by capillary
gas chromatography using a GC2010 Gas Chromatograph
(Shimadzu Corporation, Columbia, Md) equipped with
a SP2560, 100-m column (Supelco, Bellefonte, Pa). FA
were identiﬁed by comparison with a standardmixture of FA
characteristic of RBCs and reported as a percentage of
total identiﬁed FA after response factor correction. The
typical coefﬁcient of variation for the high-sensitivity
omega-3 index (eicosapentaenoic acid þ docosahexaenoic
acid) using this procedure is 3%. The average omega-3 index
in the U.S. population is 4.5%, with values ranging from
2.7% in the lowest ﬁfth percentile to 8.8% in the highest
95th percentile.30
Inﬂammatory markers. Inﬂammatory markers studied
included CRP, IL-6, sICAM-1, and tumor-necrosis-factor
(TNF)-a. Selection of these inﬂammatory biomarkers was
based on demonstrated evidence by our group that PUFA
alter IL-6, ICAM-1, and TNF-a gene expression in endo-
thelial cells31 and work by Farzaneh-Far et al that circulating
CRP and IL-6 are associated with n-3 PUFA in patients with
CAD.22 Ten milliliters of whole venous blood were collected
in a fasting state in a tiger-top tube, clotted for a minimum of
30 minutes at room temperature, and centrifuged at
2800 rpm for 10minutes at 4C. Serumwas stored at80C
until assayed for IL-6, sICAM-1, and TNF-a per standard kit
protocol (R&D Systems, Inc, Minneapolis, Minn). The
typical coefﬁcients of variation for IL-6, sICAM-1, and TNF-
a are 7.4%, 4.6%, and 5.4%, respectively. The lower limits of
detection are 0.04 pg/mL, 0.1 ng/mL, and 0.11 pg/mL,
respectively. Plasma was assayed for CRP the same day as
collection by the SF VAMC lab per standard methodology
(Beckman Coulter Analyzer; Beckman Coulter, Inc, Miami,
Fla). The coefﬁcient of variation forCRPusing this procedure
is 5.1%. Normal range values for CRP are as follow: levels less
than 1mg/L are considered “low,” levels from1-3mg/L are
considered “average,” and levels greater than 3 mg/L are
considered “high” and are associated with an increased risk of
cardiovascular events.32,33 The normal value for IL-6 is less
than 7 pg/mL.
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and standards.24,34 Systolic blood pressures of the brachial,
posterior tibial, and dorsalis pedis arteries were measured
bilaterally. For each lower extremity, the highest systolic
pressure of the two pedal pulses was divided by the highest
systolic pressure of the two brachial arteries.
Renal, lipid, and metabolic measurements. Blood
samples were collected in a fasting state for measurement
of creatinine (Cr), estimated glomerular ﬁltration rate,
calculated using the abbreviated Modiﬁcation of Diet in
Renal Disease (MDRD) formula based on age, sex, race,
and serum creatinine level,35 albumin, total cholesterol,
triglycerides, low-density lipoprotein (LDL), high-density
lipoprotein, and hemoglobin A1C if patients were dia-
betic. Plasma was assayed for these analytes on the same day
as collection by the SF VAMC lab per standard method-
ology (Beckman Coulter Analyzer; Beckman Coulter, Inc).
Serumwas isolated at the same time points for homocysteine
and assayed the same day as collection by the SF VAMC lab
per standard methodology (Abbott Diagnostics Architect
i1000 Analyzer; Abbott Diagnostics, Lake Forest, Ill).
Vascular reactivity of brachial arteries. Flow-
mediated vasodilation was performed according to current
guidelines and standards36,37 as already described by our
group6 and other investigators.38 Subjects were asked to
fast ($8 hours) and be free of nicotine ($4 hours). A
history of recent medications was recorded. Subjects were
allowed to rest for 10 minutes in a supine position in
a darkened room with temperature maintained at 23C.
Each subject’s arm was extended onto a movement-
constraining pillow with the palmar aspect oriented ante-
riorly. A 5-cm tourniquet blood pressure cuff was placed
on the upper arm distal to the insertion of the deltoid.
Prior to cuff inﬂation, the baseline vessel diameter and
blood-ﬂow velocity were recorded for 60 seconds using
EKG-gated image capture software (Brachial Imager;
Medical Imaging Applications LLC, Coralville, Iowa). The
blood pressure cuff was then inﬂated to 50 mm Hg above
the subject’s systolic blood pressure and maintained for
a period of 5 minutes. Blood-ﬂow velocity was assessed for
a period of 30 seconds postcuff release using the methods
described above and B-mode images for 3 minutes post-
cuff release.
Analysis of the images was performed using continuous
edge-detection software (Brachial Analyzer, Medical
ImagingApplications LLC).Hyperemia diameter was calcu-
lated using a predetermined time window (55-65 seconds
postcuff release). FMD percentage was calculated as [(60 s
hyperemia diameter-average baseline diameter)/average
baseline diameter]  100. The vasoreactivity index was
calculated by normalizing FMD to brachial stimulus ratio,
with brachial stimulus ratio corresponding to hyperemia
ﬂow divided by baseline ﬂow. Time-averaged velocity
measurements were obtained using the peak-velocity
method. Velocity of the hyperemia stimulus was calculated
as the mean velocity of the ﬁrst four heartbeats following
cuff release. Both mean velocity and the velocity time
integral were recorded.Statistical analysis
For descriptive purposes, we categorized participants
by tertiles of the omega-3 index. Differences in characteris-
tics among these groups were compared using analysis of
variance for continuous variables and Fisher exact test for
dichotomous variables. We then used linear models to
estimate the relationship between decreases in the
omega-3 index, rescaled by its standard deviation (SD),
and the four inﬂammatory markers, all log-transformed
to meet normality assumptions. After back-transformation
using the equation 100  [eß-1], the resulting regression
coefﬁcients are interpretable as percentage changes in the
marker for each SD decrease in the omega-3 index. Cova-
riates were retained in the model if omitting them changed
the adjusted coefﬁcient for the omega-3 index by more
than 5%. The same approach was also used to estimate
the association of the omega-3 index with FMD. In addi-
tion, we used the Kruskal‒Wallis test to evaluate differences
in CRP levels across the three omega-3 index categories
proposed by Harris et al (deﬁned as <4%, 4%-8%, >8%,
corresponding to high, intermediate, and low CAD risk,
respectively21). Finally, having previously shown that
patients with PAD and elevated CRP values have adverse
cardiovascular and revascularization outcomes,23,39 we
used both unadjusted and fully adjusted logistic models
to estimate the association of the omega-3 index with
an elevated CRP (>5 mg/dL). Statistical analyses were
performed using Stata/SE 12 (StataCorp, College
Station, Tex).
RESULTS
A total of 64 patients that were referred for PAD eval-
uation at the vascular surgery clinic of the SF VAMC were
recruited for the study (61 claudicants and 3 CLIs). The
mean CRP level was 5.0 6 5.0 mg/L (median
3.3 mg/L) and the mean omega-3 index was 5.0% 6
1.8% (median 4.5%). One patient had missing inﬂamma-
tory marker values and was excluded from further analysis.
The baseline characteristics of patients with PAD are
summarized in Table I by omega-3 index tertiles. The
patients in the lowest tertile were more likely to be
younger, have a history of smoking, and have a higher
score on the Patient Health Questionnaire-9 (greater
depression burden). They also had higher CRP and glucose
values and a trend towards higher levels of homocysteine
(Table II). Scatter plots of log-CRP, log-IL6, log-ICAM,
and log-TNF-a against the omega-3 index are shown in
the Fig. CRP was inversely correlated with the omega-3
index. There was no statistical difference across tertiles of
omega-3 index in brachial artery FMD and ABI measure-
ments (Table III).
In an unadjusted model, the omega-3 index was signif-
icantly associated with CRP (38% increase in CRP for
a 1.8% decrease in the omega-3 index; P ¼.007)
(Table IV). After adjustment for age, body mass index,
smoking, index ABI, and high-density lipoprotein, we
found an independent inverse association between the
Table II. Laboratory values and biomarkers of the population categorized by tertiles of the omega-3 index
Tertile I
3.7 6 0.3 (n ¼ 21)
Tertile II
4.5 6 0.3 (n ¼ 21)
Tertile III
6.8 6 2.0 (n ¼ 21) P value
General laboratory values
Cholesterol, mg/dL 162 6 36 174 6 39 145 6 41 .06
LDL, mg/dL 89 6 29 98 6 38 75 6 36 .11
HDL, mg/dL 40 6 9 43 6 17 47 6 15 .31
Triglycerides, mg/dL 171 6 119 174 6 94 118 6 73 .12
Serum creatinine, mg/dL 1.0 6 0.3 1.2 6 0.4 1.0 6 0.2 .19
eGFR, mL/min 84 6 29 70 6 27 78 6 23 .29
Homocysteine 15 6 7 14 6 4 12 6 3 .08
Glucose 123 6 83 81 6 53 72 6 32 .05
Inﬂammation
Log-CRP, mg/L 1.4 6 0.9 1.4 6 0.8 0.6 6 1.1 .01
Log-IL-6, pg/mL 0.4 6 0.4 0.5 6 0.5 0.2 6 0.5 .14
Log-ICAM 2.5 6 0.4 2.5 6 0.3 2.4 6 0.4 .42
Log-TNF-a, pg/mL 0.8 6 0.3 0.7 6 0.5 0.6 6 0.4 .39
CRP, C-reactive protein; DHA, docosahexaenoic acid; eGFR, estimated glomerular ﬁltration rate; EPA, eicosapentaenoic acid; ICAM, intercellular adhesion
molecule; IL, interleukin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RBC, red blood cell; SD, standard deviation; TNF, tumor-necrosis-
factor.
Values are presented as mean 6 SD or number (%).
The omega-3 index is the sum of EPAþDHA in RBC membranes.
Table I. The baseline characteristics of the PAD patients categorized by tertiles of the omega-3 index
Characteristics
Tertile I
3.7 6 0.3 (n ¼ 21)
Tertile II
4.5 6 0.3 (n ¼ 21)
Tertile III
6.8 6 2.0 (n ¼ 21) P value
Age, mean 6 SD 64 6 8 68 6 9 70 6 8 .05
Male sex (%) 21 (100) 21 (100) 21 (100) NA
Caucasian 15 (71) 16 (76) 15 (71) 1.0
Rutherford classiﬁcation 1.9 6 0.8 2.4 6 0.9 2.1 6 0.9 .23
Comorbidities
Hypertension 19 (90) 18 (86) 21 (100) .35
Hyperlipidemia 18 (86) 18 (86) 19 (90) 1.0
History of CAD 6 (29) 6 (29) 10 (48) .37
Diabetes mellitus 5 (24) 6 (29) 9 (43) .49
History of previous lower extremity bypass 4 (19) 5 (24) 1 (5) .31
History of previous lower extremity percutaneous procedure 7 (33) 5 (24) 7 (33) .83
Current and past history of smoking 21 (100) 21 (100) 17 (81) .03
Medications
Aspirin 14 (67) 11 (55) 13 (62) .76
Ace-inhibitor 7 (33) 7 (35) 10 (48) .65
b-Blocker 13 (62) 7 (35) 14 (67) .10
Statin 19 (90) 16 (80) 19 (90) .57
Anthropometric measures and behavioral health
BMI 25 6 4 28 6 4 28 6 5 .08
Waist-hip ratio 0.98 6 0.04 1.02 6 0.07 1.00 6 0.04 .20
PHQ-9 11 6 7 2 6 3 5 6 7 .03
BMI, Body mass index; CAD, coronary artery disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PAD, peripheral artery disease; PHQ, Patient
Health Questionnaire; RBC, red blood cell; SD, standard deviation.
Values are presented as mean 6 SD or number (%).
The omega-3 index is the sum of EPAþDHA in RBC membranes.
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evidence for independent associations between the
omega-3 index and IL-6 (22% increase in IL-6 for a 1.8%
decrease in the omega-3 index; P ¼ .001). There was no
signiﬁcant correlation found between the omega-3 index
and brachial FMD (unadjusted: 0.26; adjusted: 0.79).
There was also no evidence of an interaction between the
omega-3 index and CRP on this end point.It is known that patients with elevated CRP values have
adverse cardiovascular and revascularization outcomes.23,39
Each SD decrease (1.8%) in the omega-3 index was associ-
ated with having an increased likelihood of elevated CRP
using a cutoff of 5 mg/L, although this did not reach
signiﬁcance (unadjusted odds ratio 2.0; 95% conﬁdence
interval, 0.9-4.5; P ¼ .10; adjusted odds ratio 8.6, 95%
conﬁdence interval, 0.7-10.5; P ¼ .09).
Fig. Correlations between the omega-3 index and log-C-reactive protein (CRP) (A), log- interleukin (IL)-6 (B), log-
intercellular adhesion molecule (ICAM)-1 (C), log-tumor-necrosis-factor (TNF)-a (D). The omega-3 index is the sum
of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell (RBC) membranes.
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This report is the ﬁrst to examine the relationship
between the omega-3 index and systemic inﬂammation
and endothelial function in a PAD cohort. In a cross-
sectional cohort of patients presenting for evaluation of
PAD in an outpatient vascular surgery clinic, we found
a signiﬁcant inverse association between the omega-3 index
and inﬂammation as measured with CRP and IL-6. Our
ﬁndings suggest that diet could play an important role in
the inﬂammatory proﬁle of patients with PADbased on their
circulating proinﬂammatory biomarkers levels. Although
a dietary intervention was not tested in this study, it is
possible that manipulation of the omega-3 index, which
can be accomplished by increasing consumption of ﬁsh or
supplementation with ﬁsh oil40,41 could have beneﬁcial
effects in this patient population. Trials are warranted to
test this hypothesis.
Despite attempts at treatment with available medical
therapies, patients with PAD continue to have a higher
risk of cardiovascular events compared with patients with
CAD alone.2,3 Inﬂammation is known to have a signiﬁcant
association with disease burden in patients with PAD.
Inﬂammation in general, and CRP in particular, has been
correlated with impaired endothelial function in vivo and
in vitro,42,43 and inﬂammatory markers, including CRP,
are known to be elevated in patients with PAD.4-6 Further-
more, in a recent paper by Owens et al, CRP was found to
be a strong predictor of mortality in patients with PAD.23
Other authors have also reported increased mortality in
PAD patients with higher inﬂammatory biomarker
levels.11,44 In our study, CRP and IL-6 were signiﬁcantlyassociated with the omega-3 index, but TNF-a and
ICAM-1 were not. The failure to demonstrate a signiﬁcant
association between TNF-a and ICAM-1 and the omega-3
index may be related to the relative predictive value of indi-
vidual biomarkers, as was demonstrated in the Edinburgh
Artery Study.10
In the present study, we could not demonstrate a signif-
icant association between the omega-3 index and endothe-
lial function. We believe that this could be due to either the
absence of an association, the relatively small number of
patients in the study, or the fact that the endothelial function
in our cohort was so low as to not be affected by this vari-
able. Although our results did not demonstrate an associa-
tion between omega-3 index and markers of endothelial
function using FMD, previous authors have detected
a signiﬁcant correlation in non-PAD cohorts. In one study
of young, healthy smokers, Siasos et al found that FMD
values had signiﬁcantly improved after oral treatment with
2 gm/d of n-3 PUFA for several months.20 The presumed
mechanism of action is that n-3 FA may decrease the
elevated oxidative stress caused by smoking and thereby
improve endothelial function. N-3 PUFA supplementation
could lead to recovery of endothelial synthesis of nitrous
oxide and prostaglandin 12, as well as vascular smooth
muscle cell sensitivity to nitrous oxide. These mechanisms
are especially relevant to the cohort evaluated in our study,
96% (n ¼ 67) of whom were current or past smokers and
who, as a result, have pro-inﬂammatory proﬁles. The results
in smokers reported by Siasos et al20 indicate that supple-
mentation could, in theory, lead to beneﬁts in patients
with PAD and should be examined prospectively.
Table III. Noninvasive vascular measurements categorized by tertiles of the omega-3 index
Tertile I
3.7 6 0.3 (n ¼ 21)
Tertile II
4.5 6 0.3 (n ¼ 21)
Tertile III
6.8 6 2.0 (n ¼ 21) P value
Flow-mediated brachial artery vasodilation
Brachial FMD, % 6 6 5 8 6 3 8 6 5 .46
Brachial stimulus ratio 4 6 2 5 6 2 6 6 3 .13
Vasoreactivity index 1.5 6 1.4 2.2 6 1.9 1.6 6 1.2 .37
Brachial artery baseline diameter, cm 0.39 6 .06 0.37 6 .07 0.38 6 .05 .66
Brachial artery reactive hyperemia diameter, cm 0.41 6 0.06 0.40 6 0.07 0.40 6 0.05 .80
Brachial artery baselinevelocity, m/s 0.17 6 0.06 0.15 6 0.08 0.13 6 0.04 .26
Brachial artery reactive hyperemia velocity, m/s 0.7 6 0.3 0.6 6 0.2 0.7 6 0.2 .26
Brachial artery baseline ﬂow, mL/min 119 6 50 100 6 67 87 6 33 .18
Brachial artery reactive hyperemia ﬂow, mL/min 556 6 261 454 6 208 548 6 254 .38
Brachial artery baseline shear stress, dynes/cm2 12 6 4 11 6 7 10 6 4 .41
Brachial artery reactive hyperemia shear stress, dynes/cm2 51 6 25 41 6 16 48 6 16 .33
Blood pressure and ABIs
Systolic blood pressure, mm Hg 137 6 20 132 6 17 138 6 21 .53
Diastolic blood pressure, mm Hg 76 6 12 77 6 7 76 6 7 .97
Index ABI 0.65 6 0.25 0.76 6 0.11 0.67 6 0.15 .12
Mean ABI 0.75 6 0.22 0.86 6 0.11 0.74 6 0.15 .05
ABI, Ankle-brachial index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FMD, ﬂow-mediated dilation; RBC, red blood cell; SD, standard
deviation.
Values are presented as mean 6 SD or number (%).
The omega-3 index is the sum of EPAþDHA in RBC membranes.
Table IV. Percent change in inﬂammatory markers by per SD (1.8%) decrease in the omega-3 index
Inﬂammatory markera
Unadjusted Adjustedb
% Increase 95% CI P value % Increase 95% CI P value
CRP 38 9, 75 .007 33 1, 75 .04
IL 10 3, 24 .13 22 8, 38 .001
ICAM-1 5 4, 15 .31 1 8, 10 .87
TNF-a 4 6, 14 .45 2 9, 15 .71
ABI, Ankle-brachial index; BMI, body mass index; CAD, coronary artery disease; CI, conﬁdence interval; CRP, C-reactive protein; DHA, docosahexaenoic
acid; eGFR, estimated glomerular ﬁltration rate; EPA, eicosapentaenoic acid; ICAM, intercellular adhesion molecule; IL, interleukin; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; RBC, red blood cell; SD, standard deviation; TNF, tumor-necrosis-factor.
The omega-3 index is the sum of EPAþDHA in RBC membranes.
aInﬂammatory markers were log-transformed.
bAdjustment variables include age, BMI, smoking, index ABI, and HDL (CRP); age, BMI, smoking, index ABI, and eGFR (IL-6); age, BMI, smoking, index
ABI, race, history of CAD, and LDL (ICAM-1); and age, BMI, smoking, index ABI, systolic blood pressure, beta blockers, homocysteine, and creatinine
(TNF-a).
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speciﬁcally targeted by existing guideline-directed phar-
macotherapies. For example, the American Heart Associa-
tion/American College of Cardiology guidelines
published in 2006 recommend a LDL goal of <100 mg/
dL for all patients with PAD.45 Feringa and colleagues
demonstrated that in patients with PAD, higher doses of sta-
tins and lower LDL cholesterol levels are both indepen-
dently associated with improved outcomes,46 but the
effects of cholesterol-lowering per se on inﬂammatory status
is unclear. In the present study, 80%-90% of the patients
were taking statins and mean total cholesterol and LDL
levels were within guidelines, but inﬂammatory markers
were still elevated. The relationship that we found between
the omega-3 index and CRP in patients with PAD suggests
several avenues for future research; therapy aimed at
lowering inﬂammatory biomarkers (eg, CRP) could be
explored, as well as more aggressive statin therapy in allpatients with PAD using a goal of LDL<70 mg/dL as rec-
ommended by the Third Report of Expert Panel on Detec-
tion, Evaluation and Treatment of High Blood Cholesterol
in Adults guidelines.47 As noted earlier, based on previous
studies demonstrating that ﬁsh or ﬁsh oil consumption
have the potential to increase the omega-3 index,40,41 nutri-
tional supplementation with n-3 PUFA or diet modiﬁcation
could possibly lead to an improvement in the levels of circu-
lating inﬂammatory biomarkers in the PAD population.
It is also important to note that although cholesterol
levels were not signiﬁcantly different by tertiles of omega-
3 index in our study, some authors have demonstrated
that triglyceride levels are negatively associated and a history
of hypercholesterolemia is positively associated with the
omega-3 index.39 Further studies are needed to better
understand this relationship between cholesterol levels
and omega-3 index, as well as the impact of statins on
the omega-3 index levels.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 5 Grenon et al 1289Several lines of evidence support the beneﬁcial effect of
n-3 PUFA on inﬂammation and atherosclerotic burden. We
have recently demonstrated that supplementation with n-3
PUFA in vitro leads to decreased adhesion of monocytes
to the endothelial monolayer.31 Serhan et al have also
made novel discoveries in the ﬁeld of inﬂammation with
the “resolution-phase interaction products” (resolvins)
pathways.17-19 This new paradigm describes the transition
from acute to chronic inﬂammation as involving the loss of
endogenously operative resolution processes. This response
aims to re-establish homeostasis through resolution of an
acute inﬂammatory response. Lipid autacoids are at the
core of these responses as lipoxins and resolvins are thought
to be bioactive products of n-6 and n-3 FA,17,19 respec-
tively. In support of this observation, plasma levels of the
pro-resolving mediator 15-epimeric lipoxin were signiﬁ-
cantly lower in patients with symptomatic PAD than
in healthy volunteers, suggesting a “resolution deﬁcit” in
PAD.5 Considering this evidence, changes in n-3 PUFA
intake will likely inﬂuence the balance of proinﬂammatory
and pro-resolving mediators, potentially leading to clinical
improvement in chronic inﬂammatory states such as
atherosclerosis.
Limitations. The patient population studied was not
representative of the wider PAD population as it included
only male veterans from SF VAMC. These men were
predominantly Caucasian and likely had similar diets.
Furthermore, the inﬂammatory phenotype of the popula-
tion studied at the SF VAMC may be skewed compared
with the typical PAD patient with regards to levels of
psychological and psychosocial factors affecting overall
stress and inﬂammation.48 The correlation coefﬁcient
values were low and limit any conclusions about the rela-
tionships between the various inﬂammatory mediators and
the omega-3 index.
CONCLUSIONS
In a cross-sectional study of patients with PAD, the
omega-3 index was inversely associated with plasma levels
of CRP and IL-6. There were no signiﬁcant relations
with other inﬂammatory biomarkers or with measures of
vascular/endothelial function. Because patients with PAD
and elevated CRP values are at higher risk for cardiovas-
cular and revascularization outcomes, further studies are
needed to determine if manipulation of omega-3 index
via dietary changes or ﬁsh oil supplementation could
reduce vascular inﬂammation and related symptoms.
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